Abstract
Positron emission tomography (PET) is a functional imaging modality that measures pathophysiology status of disease noninvasively, and has become a key component for innovative drug delivery system (DDS) studies recently. The development of multifunctional chelating agents is critical for developing PET radiopharmaceuticals and therefore has become a hot and demanding research topic recently. The optimal chelators should be readily attached to biomolecules covalently, able to form stable complexes with radiometals, and demonstrate good bio-distribution pattern in vivo. Indeed, the selection of suitable chelators can facilitate the development of an effective PET imaging probe by improving targeting properties and providing favorable in vivo pharmacokinetics of radiolabeled probes. This review focuses on the recent developments of multifunctional chelators that are suitable for both imaging and radiation therapy.
Keywords: Positron emission tomography, drug-delivery system, multifunctional chelating agents, radiation therapy, radiometals, radiochemistry.
Current Drug Targets
Title:Matching Chelators to Radiometals for Positron Emission Tomography Imaging- Guided Targeted Drug Delivery
Volume: 16 Issue: 6
Author(s): Huaifu Deng, Hui Wang and Zibo Li
Affiliation:
Keywords: Positron emission tomography, drug-delivery system, multifunctional chelating agents, radiation therapy, radiometals, radiochemistry.
Abstract: Positron emission tomography (PET) is a functional imaging modality that measures pathophysiology status of disease noninvasively, and has become a key component for innovative drug delivery system (DDS) studies recently. The development of multifunctional chelating agents is critical for developing PET radiopharmaceuticals and therefore has become a hot and demanding research topic recently. The optimal chelators should be readily attached to biomolecules covalently, able to form stable complexes with radiometals, and demonstrate good bio-distribution pattern in vivo. Indeed, the selection of suitable chelators can facilitate the development of an effective PET imaging probe by improving targeting properties and providing favorable in vivo pharmacokinetics of radiolabeled probes. This review focuses on the recent developments of multifunctional chelators that are suitable for both imaging and radiation therapy.
Export Options
About this article
Cite this article as:
Deng Huaifu, Wang Hui and Li Zibo, Matching Chelators to Radiometals for Positron Emission Tomography Imaging- Guided Targeted Drug Delivery, Current Drug Targets 2015; 16 (6) . https://dx.doi.org/10.2174/1389450116666150707100702
DOI https://dx.doi.org/10.2174/1389450116666150707100702 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cellular Functions of Vaults and their Involvement in Multidrug Resistance
Current Drug Targets Transdermal Drug Delivery: A Step towards Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Meet Our Editorial Board Member
Current Drug Delivery Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Nose-to-Brain Drug Delivery by Nanoparticles in the Treatment of Neurological Disorders
Current Medicinal Chemistry Hypericin - The Facts About a Controversial Agent
Current Pharmaceutical Design Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Cellular Changes, Molecular Pathways and the Immune System Following Photodynamic Treatment
Current Medicinal Chemistry Genome and Transcriptome Analysis of Neuroblastoma Advanced Diagnosis from Innovative Therapies
Current Pharmaceutical Design Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Current Cancer Drug Targets Delivery of Large Genomic DNA Inserts > 100 kb Using HSV-1 Amplicons
Current Gene Therapy Targeted Drug Delivery for Breast Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Identification of Novel Drug Targets for Angiostatic Cancer Therapy; It Takes Two to Tango
Current Pharmaceutical Design Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience
Current Drug Targets BUB1B Promotes Proliferation of Prostate Cancer via Transcriptional Regulation of MELK
Anti-Cancer Agents in Medicinal Chemistry miR-149 as a Potential Molecular Target for Cancer
Current Medicinal Chemistry Cancer Stem Cells in Prostate Cancer Chemoresistance
Current Cancer Drug Targets Nanoparticles in Cancer
Current Radiopharmaceuticals Expression of Specificity Protein Transcription Factors in Pancreatic Cancer and their Association in Prognosis and Therapy
Current Medicinal Chemistry Drug Targeting to the Brain - A Review
Current Nanoscience